<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-21 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-21</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-21</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <p><strong>Paper ID:</strong> paper-64df15affb9dc44c0bc780c6de07026c16d6e416</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/64df15affb9dc44c0bc780c6de07026c16d6e416" target="_blank">Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Immunology</p>
                <p><strong>Paper TL;DR:</strong> Pre-clinical and translational studies are presented that highlight the critical role of TRM in both immune control of primary melanoma and as a key CD8+ T cell subset that mediates anti-tumor activity of ICIs for the treatment of melanoma.</p>
                <p><strong>Paper Abstract:</strong> Tissue-resident memory T (TRM) cells have emerged as key players in the immune control of melanoma. These specialized cells are identified by expression of tissue retention markers such as CD69, CD103 and CD49a with downregulation of egress molecules such as Sphingosine-1-Phosphate Receptor-1 (S1PR1) and the lymphoid homing receptor, CD62L. TRM have been shown to be integral in controlling infections such as herpes simplex virus (HSV), lymphocytic choriomeningitis virus (LCMV) and influenza. More recently, robust pre-clinical models have also demonstrated TRM are able to maintain melanoma in a dormant state without progression to macroscopic disease reminiscent of their ability to control viral infections. The discovery of the role these cells play in anti-melanoma immunity has coincided with the advent of immune checkpoint inhibitor (ICI) therapy which has revolutionized the treatment of cancers. ICIs that target programmed death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) have led to substantial improvements in outcomes for patients with metastatic melanoma and have been rapidly employed to reduce recurrences in the resected stage III setting. While ICIs mediate anti-tumor activity via CD8+ T cells, the specific subsets that facilitate this response is unclear. TRM invariably exhibit high expression of immune checkpoints such as PD-1, CTLA-4 and lymphocyte activating gene-3 (LAG-3) which strongly implicates this CD8+ T cell subset as a crucial mediator of ICI activity. In this review, we present pre-clinical and translational studies that highlight the critical role of TRM in both immune control of primary melanoma and as a key CD8+ T cell subset that mediates anti-tumor activity of ICIs for the treatment of melanoma.</p>
                <p><strong>Cost:</strong> 0.038</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e21.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e21.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN-neo (optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Multicenter phase II neoadjuvant dose-finding trial testing different ipilimumab+nivolumab dosing schedules in macroscopic stage III resectable melanoma; compared tolerability and pathologic response across schedules and informed preferred neoadjuvant regimen.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo)</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo)</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Rozeman et al., Lancet Oncology 2019</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2019</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Multicentre, phase II randomized dose-finding trial</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Three neoadjuvant dosing schedules of ipilimumab + nivolumab (Arm A: ipi 3 mg/kg + nivo 1 mg/kg; Arm B: ipi 1 mg/kg + nivo 3 mg/kg; Arm C: sequential ipi 3 mg/kg then nivo 3 mg/kg), with two cycles given preoperatively (dose-schedule comparison).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with macroscopic resectable stage III melanoma (operable lymph node disease)</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Macroscopic stage III (clinical/radiologic operable nodal disease); trial used macroscopic stage III criteria (per OpACIN-neo protocol as cited).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>99</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Approximately 99 total across 3 arms (≈33 per arm)</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Combination ipilimumab + nivolumab with dose-schedules varying by arm (see arms_description); two cycles administered preoperatively.</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>Two neoadjuvant cycles (schedule dependent), administered over several weeks prior to surgery (dose interval per protocol; exact timing not specified in review).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Patients proceeded to surgery and then adjuvant therapy per protocol/standard; specifics not detailed in review.</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Not reported in review (pCR not explicitly stated overall); reported outcome: pathologic complete response for Arm B reported as 57% in review text (Arm B pCR = 57%).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic complete response (pCR) and safety (grade 3-4 TRAEs) reported; pathologic response used as endpoint in neoadjuvant context.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Not detailed in review beyond demonstrating high pathologic responses with optimized dosing and acceptable safety for Arm B; supports neoadjuvant use because of high pCR rates.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>Grade 3-4 TRAEs: Arm B 20%; Arm A 38%; Arm C 50% (reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Dose-finding phase II with modest sample size and heterogeneous arms; review notes tolerability and pCR but longer-term survival data not provided in review.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management', 'publication_date_yy_mm': '2022-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e21.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e21.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PRADO</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Personalized Response-Directed Surgery and Adjuvant Therapy after Neoadjuvant Ipilimumab and Nivolumab (PRADO)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase II single-arm trial applying neoadjuvant ipilimumab+nivolumab with response-directed surgical and adjuvant management in high-risk stage III melanoma, using pathologic response in the index lymph node to guide omission of completion lymph node dissection or adjuvant therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>PRADO</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Reijers et al., Nature Medicine 2022</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2022</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Phase II, single-arm, response-directed neoadjuvant study</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Single neoadjuvant arm: two doses of ipilimumab 1 mg/kg + nivolumab 3 mg/kg followed by index lymph node (ILN) surgery and response-directed further surgery/adjuvant: MPR (≤10% viable tumor) → no TLND nor adjuvant; pPR (>10%–≤50% viable) → TLND alone; pNR (≥50% viable) → TLND + adjuvant systemic therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with resectable high-risk stage IIIB–IIID melanoma (macroscopic nodal disease)</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Stage IIIB–IIID (AJCC staging as per trial inclusion); operable nodal disease permitting ILN biopsy/resection.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>99</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Single-arm (n=99 total); response-directed post-op management subsets (MPR/pPR/pNR counts not fully enumerated in review).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Ipilimumab 1 mg/kg + nivolumab 3 mg/kg, two doses preoperatively.</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>Two doses given preoperatively; response assessment after six weeks with resection of the index lymph node at that time.</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Response-directed: omitted in MPR patients; TLND alone for pPR; TLND followed by adjuvant systemic therapy for pNR patients.</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td>Index lymph node resection and response assessment at ~6 weeks after neoadjuvant start.</td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>Strategy enabled omission of therapeutic lymph node dissection (TLND) and adjuvant therapy in patients with major pathological response; the trial reports a reduction in surgical morbidity by omitting TLND in MPR patients (specific rates not given in review).</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>Major pathological response (MPR) defined as ≤10% viable tumor in ILN; pPR defined as >10% to ≤50% viable tumor; pNR ≥50% viable tumor.</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>MPR rate 61% (95% CI 50–70%) as reported in review.</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Strong association reported: 2-year RFS and DMFS for MPR were excellent (RFS 93% and DMFS 98%); for pPR RFS and DMFS were both 64% at 2 years; overall 2-year RFS and DMFS for all surgically treated patients were 85% and 89% respectively.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response rates (primary), 2-year recurrence-free survival (RFS) and distant metastasis-free survival (DMFS).</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>2-year RFS reported by pathologic response subgroup: MPR 93%; pPR 64%; overall surgically treated 85% at 2 years.</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td>2-year DMFS by subgroup: MPR 98%; pPR 64%; overall surgically treated 89% at 2 years.</td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors used pathologic response to infer durable systemic benefit and support de-escalation of surgery/adjuvant therapy; implication that early tumor exposure to ICI generates strong local tumor immunity predicting systemic control.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>PRADO reported a strategy that reduced the need for TLND and adjuvant therapy in responders; explicit surgical complication rates or delays not provided in review.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Single-arm design without randomized adjuvant-only comparator; relatively short follow-up in review; response-directed algorithm requires validation in randomized trials.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management', 'publication_date_yy_mm': '2022-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e21.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e21.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>INMC pooled analysis</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>INMC pooled analysis of neoadjuvant melanoma trials (Pathological response and survival with neoadjuvant therapy in melanoma)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Pooled analysis of six neoadjuvant melanoma trials (including anti-PD-1 monotherapy, ipilimumab+nivolumab, and BRAF-MEK targeted therapy) that assessed pathologic response as a surrogate for relapse-free survival (RFS).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the international neoadjuvant melanoma consortium (INMC)</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the international neoadjuvant melanoma consortium (INMC)</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>Pooled INMC analysis</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Menzies et al., Nature Medicine 2021</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2021</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Pooled analysis/meta-analysis of six neoadjuvant trials (various regimens)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Pooled cohorts: anti-PD-1 monotherapy (n=37), combination ipilimumab+nivolumab (n=104), and BRAF-MEK inhibitors (n=51) given neoadjuvantly; surgical resection then adjuvant as per trial.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with resectable stage III melanoma enrolled across six neoadjuvant trials (heterogeneous populations across trials).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Resectable stage III disease across included trials (individual trial criteria heterogeneous).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>192</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Anti-PD-1 n=37; Ipi-Nivo n=104; BRAF-MEKi n=51 (as reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Varied: anti-PD-1 monotherapy, ipilimumab+nivolumab combination, or BRAF-MEK inhibitors (regimens per constituent trials).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>Heterogeneous across pooled studies; not standardized in review.</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant therapy varied by trial; pooled analysis focused on neoadjuvant pathologic response and subsequent outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>pCR and categories including near pCR and partial pathological response (definitions heterogeneous across trials; review notes near pCR/pPR distinctions used in analysis).</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Strong association: patients achieving pCR had superior 2-year RFS (89% vs 50% for non-pCR; p<0.001). For immunotherapy-treated patients, near pCR or partial pathological response also associated with excellent 2-year RFS (>90%). For targeted therapy, non-pCR patients had poor 2-year RFS (13%).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response rates and relapse-free survival (RFS) at 2 years; event-free survival not detailed in review.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>2-year RFS: pCR group ~89% vs non-pCR ~50% (pooled data); immunotherapy responders (pCR/near pCR/pPR) 2-year RFS ~96% as reported for combined immunotherapy responders.</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td>Median follow-up reported in review: 20.9 months (pooled analyses).</td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Review emphasizes pathologic response as a surrogate for RFS; mechanistic immune correlates varied across included trials and not exhaustively summarized in review.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors infer that early tumor exposure to immunotherapy producing pathologic responses predicts durable systemic disease control, supporting neoadjuvant strategies and use of pathologic response as a surrogate endpoint.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td>Pooled heterogeneous data; targeted therapy responders behaved differently than immunotherapy responders (non-pCR targeted therapy patients had poor outcomes), indicating modality-specific implications of pathologic response.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Heterogeneity across trials (regimens, definitions of pathologic response, follow-up), limited median follow-up (~21 months), and non-randomized pooled data limit causal inference versus adjuvant-only strategies.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management', 'publication_date_yy_mm': '2022-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e21.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e21.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NeoTrio</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NeoTrio (neoadjuvant pembrolizumab alone vs sequential vs concurrent dabrafenib-trametinib + pembrolizumab) phase II</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized phase II trial in resectable BRAF V600-mutant stage III melanoma testing pembrolizumab alone, sequential dabrafenib-trametinib then pembrolizumab, or concurrent dabrafenib-trametinib with pembrolizumab as six-week neoadjuvant regimens.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>NeoTrio: Randomized trial of neoadjuvant pembrolizumab alone, sequential with, or concurrent with dabrafenib + trametinib in resectable BRAF-mutant stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>NeoTrio</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Long et al., J Clin Oncol 2022 (abstract)</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2022</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Phase II randomized 3-arm trial (preliminary results reported)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Randomized 1:1:1 to (A) pembrolizumab alone (n=20), (B) sequential D+T then pembrolizumab (n=20), (C) concurrent D+T + pembrolizumab (n=20); all received six weeks neoadjuvant therapy followed by surgery and adjuvant systemic therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Resectable BRAF V600-mutant stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Stage III BRAF V600-mutant resectable nodal disease</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>60</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>n=20 per arm</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Pembrolizumab alone; sequential dabrafenib+trametinib then pembrolizumab; concurrent dabrafenib+trametinib + pembrolizumab.</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>Six weeks of neoadjuvant therapy (exact cycle counts per agent not specified in review).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Total lymph node dissection and adjuvant systemic therapy (per protocol) following surgery.</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>pCR rates: concurrent therapy 50%; pembrolizumab monotherapy 30%; sequential therapy 15% (reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>MPR rates: concurrent 55%; pembrolizumab monotherapy 40%; sequential 30% (reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Preliminary 12-month RFS and event-free survival similar across groups; longer follow-up needed to assess survival impact of pCR differences.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic complete response (pCR), major pathologic response (MPR), 12-month RFS/event-free survival (preliminary).</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td>12-month event-free survival similar across groups (no numerical values in review).</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>12-month RFS similar across all three groups (specific numbers not provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Not detailed in review; study tests whether combining targeted therapy with PD-1 blockade increases pCR rates and whether that translates to improved short-term outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Preliminary results with small per-arm sample size; short follow-up reported in review; definitive survival impact not yet demonstrated.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management', 'publication_date_yy_mm': '2022-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e21.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e21.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Luoma 2022 (Cell)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Translational study (Cell) showing that tissue-resident memory (TRM) and circulating T cells are early responders to pre-surgical (neoadjuvant) immunotherapy, supporting mechanisms by which neoadjuvant exposure may mobilize tumor-specific immunity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Luoma et al., Cell 2022</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2022</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Translational patient-sample study (pre-surgical immunotherapy specimens analyzed)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Analysis of patient tumors and blood pre- and early on-treatment with pre-surgical immunotherapy; not a randomized therapeutic comparison in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Cancer patients receiving pre-surgical (neoadjuvant) immunotherapy (melanoma among tumor types analyzed per review citation).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Patients undergoing pre-surgical immunotherapy; specific stage criteria not detailed in review.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Pre-surgical immunotherapy (agents not detailed in review summary).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Reported that TRM and circulating T cells are early responders to pre-surgical immunotherapy, providing translational evidence that neoadjuvant ICI can activate tissue and systemic T cell populations; supports mechanisms including local reactivation and likely peripheral expansion/trafficking.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td>Authors report involvement of circulating T cells as early responders alongside TRM (review summary); details of TCR expansion in blood not provided in review.</td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td>TRM populations in tumors shown to be early responders to pre-surgical ICI (review summary).</td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td>Review references early-responder behavior of TRM and circulating T cells but does not give explicit TCR clonality results for this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors claim that neoadjuvant (pre-surgical) ICI engages both local TRM and systemic T cell compartments early, supporting the concept that early exposure to tumor antigen plus checkpoint blockade can stimulate broader antitumor immunity.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Translational study; details and sample sizes not summarized in review; direct links to long-term clinical benefit require prospective validation.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management', 'publication_date_yy_mm': '2022-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e21.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e21.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Han 2021 (Nat Cancer)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Translational single-cell and TCR sequencing study showing persistent tumor- and skin-resident T cell clones after immunotherapy and identifying TRM subclusters (FOS, TOX, IFNG) with TOX and IFNG associated with improved survival; supports TRM reactivation and durable memory after ICI.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Han et al., Nature Cancer 2021</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2021</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Translational study with paired tumor, blood and vitiligo-affected skin samples, single-cell sequencing and TCR sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Analysis of matched pre- and post-treatment samples from melanoma patients treated with immunotherapy to characterize TRM and circulating memory T cells and clonotypes.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Melanoma patients with durable responses to immunotherapy (samples included tumor, blood and vitiligo skin where applicable).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Identified TRM-TOX and TRM-IFNG populations associated with improved survival; demonstrated persistent clones years after treatment implying durable immunity linked to clinical benefit.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td>Association between TRM subsets and improved survival reported (no HRs provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Single-cell clusters: TRM-FOS (TCR signaling), TRM-TOX (immune checkpoints, cytotoxicity, TRM markers) and TRM-IFNG (IFN-γ, TNF-α); TRM-TOX and TRM-IFNG associated with improved survival and likely reactivated by ICI.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td>Paired TCR sequencing showed shared T cell clones between skin TRM and circulating TEM, maintained after treatment, indicating systemic persistence of tumor-reactive clones.</td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td>TRM populations in tumor express IFN-γ, TNF-α and immune checkpoints; TRM-TOX and TRM-IFNG correlated with clinical benefit.</td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td>Shared clonotypes between skin TRM and blood TEM; clones persisted years after treatment, indicating durable TCR responses.</td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors propose that ICI reactivates TRM and circulating memory clones which persist long-term, providing durable antitumor immunity; TRM subsets with IFN/cytotoxic profiles mediate clinical benefit.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Translational observational study; associations but not causal proof that neoadjuvant exposure per se is superior to adjuvant-only for long-term outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management', 'publication_date_yy_mm': '2022-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e21.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e21.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Park 2019 (Nature)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin (preclinical)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Preclinical murine B16 melanoma studies showing TRM are necessary to maintain melanoma in immune-mediated equilibrium (dormancy); TRM depletion studies demonstrate protection is mediated by TRM independent of circulating T cells and driven by TNF-α.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Tissue-resident memory CD8(+) T cells promote melanoma-immune equilibrium in skin</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Park et al., Nature 2019</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2019</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Preclinical murine model (B16 melanoma) with TRM manipulation and imaging</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Preclinical arms with TRM over-representation, depletion of circulating T cells, imaging and functional assays to test melanoma control.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Mechanistic finding: TRM surveil skin and maintain occult melanoma in a dormant equilibrium state; control is mediated by TRM-produced TNF-α; depletion experiments show TRM (not circulating T cells) are key effectors.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td>Depletion of circulating T cells did not abrogate protection, indicating local TRM sufficiency for control.</td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td>Two-photon microscopy visualized TRM surveillance in skin regions containing melanoma cells; TRM localize at tumor sites and exert effector function.</td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>TRM maintain melanoma dormancy via local effector mechanisms (TNF-α) and are central to local immune surveillance; implies that therapies reactivating TRM (e.g., neoadjuvant ICI) could leverage local tumor antigen exposure to boost durable control.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Preclinical model (B16) may not capture full human tumor heterogeneity; translational relevance supported by human correlative studies but requires clinical validation.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management', 'publication_date_yy_mm': '2022-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e21.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e21.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Menares 2019 (Nat Commun)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Preclinical work demonstrating that TRM can amplify antitumor immunity by promoting antigen spreading via dendritic cell activation, providing a mechanistic rationale for localized tumor antigen exposure (as in neoadjuvant therapy) to broaden systemic anti-tumor responses.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Menares et al., Nature Communications 2019</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2019</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Preclinical mechanistic murine studies</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Mechanistic experiments evaluating TRM interactions with dendritic cells and subsequent antigen spreading and systemic immune activation.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Demonstrated TRM-driven antigen spreading through dendritic cells, suggesting mechanisms by which local TRM activation (e.g., by neoadjuvant ICI) could broaden systemic tumor-specific immunity and improve outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td>Evidence of systemic antigen spreading mediated by TRM → dendritic cell axis in preclinical models.</td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td>TRM engage dendritic cells locally to drive presentation of tumor antigens and initiation of broader T cell responses.</td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td>Direct mechanistic evidence of antigen spreading initiated by TRM via dendritic cell activation (preclinical).</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors claim TRM amplify antitumor immunity by promoting antigen spreading, providing a rationale that local pre-surgical immune activation can expand systemic antitumor T cell responses.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Preclinical observations that require translation to human trials; mechanistic pathway may vary across tumor types and host contexts.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management', 'publication_date_yy_mm': '2022-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e21.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e21.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Edwards 2018 (Clin Cancer Res)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CD103+ tumor-resident CD8+ T cells associated with improved survival and expansion during anti-PD-1 treatment</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Translational human study showing CD103+ TRM are associated with improved survival in ICI-naïve melanoma patients and expand significantly during anti-PD-1 therapy, supporting TRM as effectors of PD-1 blockade.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Edwards et al., Clinical Cancer Research 2018</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2018</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Translational study of pre-treatment and early on-treatment biopsies with multiplex IHC and flow cytometry</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Observational analyses of tumor biopsies from patients treated with anti-PD-1 (and combination ICI) to evaluate TRM prevalence and dynamics.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Melanoma patients (ICI-naive and treated cohorts analyzed).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>63</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Edwards et al. found CD8+CD103+ cells increased in patients who had objective responses to ICI and these TRM signatures associated with improved survival in ICI-naive melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Correlation of TRM abundance with objective response and survival metrics (cohort analysis); expansion during anti-PD-1 therapy noted.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td>TRM signature associated with improved survival in ICI-naive patients (no HRs provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>TRM (CD103+) express immune checkpoints (PD-1, LAG-3) and expand on anti-PD-1 therapy; TRM gene signatures correlated with dendritic cell activation and IFN-γ signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td>Increased intratumoral CD8+CD103+ cells in responders; TRM located at tumor margin and express PD-1/LAG-3.</td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td>Presence/abundance of CD103+ TRM correlates with benefit; TRM gene signature predictive of improved outcomes in ICI-naive samples.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors suggest TRM are key mediators of anti-PD-1 responses due to their localization, checkpoint expression and expansion on treatment, implying neoadjuvant exposure could activate these cells in situ.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Observational/translational study (n=63 in cited cohort) and not a randomized therapeutic comparison; correlative associations require prospective validation.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management', 'publication_date_yy_mm': '2022-11'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo) <em>(Rating: 2)</em></li>
                <li>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial <em>(Rating: 2)</em></li>
                <li>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the international neoadjuvant melanoma consortium (INMC) <em>(Rating: 2)</em></li>
                <li>Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy <em>(Rating: 2)</em></li>
                <li>Tissue-resident memory CD8(+) T cells promote melanoma-immune equilibrium in skin <em>(Rating: 2)</em></li>
                <li>Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells <em>(Rating: 2)</em></li>
                <li>Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy <em>(Rating: 2)</em></li>
                <li>CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment <em>(Rating: 1)</em></li>
                <li>NeoTrio: Randomized trial of neoadjuvant pembrolizumab alone, in sequence with, or concurrent with dabrafenib plus trametinib in resectable BRAF-mutant stage III melanoma <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>